The DOI matches its Crossref record.
Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation
Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.086 · Cited by 616
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 427
Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide
Vandergriff, A., Huang, K., Shen, D., Hu, S., Hensley, M. T., Caranasos, T. G., Qian, L., & Cheng, K. (2018) · Theranostics · doi:10.7150/thno.20524 · Cited by 406
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery
Bayindir, Z. S., & Yuksel, N. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21944 · Cited by 335
Cho, H.-J., Yoon, H. Y., Koo, H., Ko, S.-H., Shim, J.-S., Lee, J.-H., Kim, K., Chan Kwon, I., & Kim, D.-D. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.028 · Cited by 304
Self-citationLiposomes: Clinical Applications and Potential for Image-Guided Drug Delivery
Lamichhane, N., Udayakumar, T., D’Souza, W., Simone II, C., Raghavan, S., Polf, J., & Mahmood, J. (2018) · Molecules · doi:10.3390/molecules23020288 · Cited by 303
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., De Santis, F., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 296
Yang, Z., Nie, S., Hsiao, W. W., & Pam, W. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s15057 · Cited by 279
Biswas, S., Dodwadkar, N. S., Deshpande, P. P., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.009 · Cited by 279
Nanoparticle transport across the blood brain barrier
Grabrucker, A. M., Ruozi, B., Belletti, D., Pederzoli, F., Forni, F., Vandelli, M. A., & Tosi, G. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1153568 · Cited by 217
“Finally, in order to increase the minimal affinity to the diseased cells and to avoid the toxic effect on non diseased tissues, an active targeting due to functionalization of the surface of the liposome is hardly needed.(128)”
BackgroundChen, H., Gao, J., Lu, Y., Kou, G., Zhang, H., Fan, L., Sun, Z., Guo, Y., & Zhong, Y. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.010 · Cited by 97
Nageeb El-Helaly, S., Abd Elbary, A., Kassem, M. A., & El-Nabarawi, M. A. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1309476 · Cited by 69
“The mean PS, PDI and ZP were determined by Zetasizer at 25 C (Malvern Instrument Ltd., Worcestershire, UK) after being diluted with PBS (Yang et al., 2007a).”
BackgroundMethodInfluentialLuiz, M. T., Abriata, J. P., Raspantini, G. L., Tofani, L. B., Fumagalli, F., de Melo, S. M. G., Emery, F. D. S., Swiech, K., Marcato, P. D., Lee, R., et al. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110038 · Cited by 63
Metadata
- Authors
- Yang, T., Choi, M.-K., Cui, F.-D., Kim, J. S., Chung, S.-J., Shim, C.-K., & Kim, D.-D.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 120
- Issue
- 3
- Pages
- 169-177
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2043371238
- Cited by
- 245
- References
- 0
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.